California-based Mirati Therapeutics Inc. plans to offer and sell its common shares in an underwritten public offering.
The clinical-stage oncology company plans to grant the underwriters an option to buy additional shares.
Cowen, Barclays and SunTrust Robinson Humphrey are acting as joint book-running managers in the offering.
